Characterization of Nanoparticles for Therapeutics
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Nanotechnology offers many advantages to traditional drug design, delivery and medical diagnostics; however, nanomedicines present considerable challenges for preclinical development. Nanoparticle constructs intended for medical applications consist of a wide variety of materials, and their small size, unique physicochemical properties and biological activity often require modification of standard characterization techniques. A rational characterization strategy for nanomedicines includes physicochemical characterization, sterility and pyrogenicity assessment, biodistribution (absorption, distribution, metabolism and excretion [ADME]) and toxicity characterization, which includes both in vitro tests and in vivo animal studies. Here, we highlight progress for a few methods that are uniquely useful for nanoparticles or are indicative of their toxicity or efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Polyethylenimine nanoparticles as efficient transfecting agents for mammalian cells
Nimesh, S., Goyal, A., Pawar, V., Jayaraman, S., Kumar, P., Chandra, R., Singh, Y. P., & Gupta, K. C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.014 · Cited by 97
RetractedNanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“For example, certain nanoparticles can permeate the leaky vasculature surrounding tumors and areas of inflammation (through what is termed the enhanced permeability and retention [EPR] effect) and many nanoparticle-based anticancer drug strategies now exploit this ‘passive targeting’ mechanism to concentrate drugs in…”
BackgroundDrug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552 · cited 1×
“Furthermore, the nanoparticle formulations might have reduced side effects and improved efficacy because the nanoparticles ‘target’ the drug to the parts of the body where it is needed [2].”
BackgroundCurrent Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,566
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Dynamic Light Scattering: With Applications to Chemistry, Biology, and Physics
Berne, B. J., & Pecora, R. (1976) · CERN Document Server (European Organization for Nuclear Research) · Cited by 2,856
Oberdörster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., Ausman, K., Carter, J., Karn, B., Kreyling, W., Lai, D., et al. (2005) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-2-8 · Cited by 2,134
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823 · cited 1×
“A comprehensive overview of nanoparticle interaction with the immune system is available in the literature [33].”
BackgroundSelf-citation
Cited by
Zhang, X.-F., Liu, Z.-G., Shen, W., & Gurunathan, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091534 · Cited by 3,220
Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“Specific arrangements of polymeric molecules at the nanoscale achieved within such materials represent unique opportunities for safe and efficient delivery of drugs, genes, and imaging molecules [1-13].”
BackgroundDobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022
Self-citationEffects of nanomaterial physicochemical properties on in vivo toxicity
Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.010 · Cited by 811
Techniques for physicochemical characterization of nanomaterials
Lin, P.-C., Lin, S., Wang, P. C., & Sridhar, R. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.11.006 · Cited by 708
Polymeric nanoparticles: A study on the preparation variables and characterization methods
Crucho, C. I. C., & Barros, M. T. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.06.004 · Cited by 696
Toxicity Assessments of Multisized Gold and Silver Nanoparticles in Zebrafish Embryos
Bar‐Ilan, O., Albrecht, R. M., Fako, V. E., & Furgeson, D. Y. (2009) · Small · doi:10.1002/smll.200801716 · Cited by 648
Xu, W., Ling, P., & Zhang, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/340315 · Cited by 595
“In recent years, nanotechnology has been widely focused on by numbers of researchers throughout the world for its superiority in increasing efficacy, specificity, tolerability, and therapeutic index of corresponding drugs [14].”
BackgroundEmerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Kus-Liśkiewicz, M., Fickers, P., & Ben Tahar, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010952 · Cited by 404
Tailoring Materials for Modulation of Macrophage Fate
Li, J., Jiang, X., Li, H., Gelinsky, M., & Gu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202004172 · Cited by 403
Current Research on Silver Nanoparticles: Synthesis, Characterization, and Applications
Dawadi, S., Katuwal, S., Gupta, A., Lamichhane, U., Thapa, R., Jaisi, S., Lamichhane, G., Bhattarai, D. P., & Parajuli, N. (2021) · Journal of Nanomaterials · doi:10.1155/2021/6687290 · Cited by 399
“However, it is also a time-consuming process, requiring high vacuum, skill, and time to prepare the ultrathin sample, and results are more reliable for homogeneous samples [104, 109, 125].”
BackgroundManson, J., Kumar, D., Meenan, B. J., & Dixon, D. (2011) · Gold Bulletin · doi:10.1007/s13404-011-0015-8 · Cited by 390
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Valencia, P. M., Basto, P. A., Zhang, L., Rhee, M., Langer, R., Farokhzad, O. C., & Karnik, R. (2010) · ACS Nano · doi:10.1021/nn901433u · Cited by 335
Nanoemulsion: An Emerging Novel Technology for Improving the Bioavailability of Drugs
Preeti, Sambhakar, S., Malik, R., Bhatia, S., Al Harrasi, A., Rani, C., Saharan, R., Kumar, S., Geeta, & Sehrawat, R. (2023) · Scientifica · doi:10.1155/2023/6640103 · Cited by 331
Fernandez-Fernandez, A., Manchanda, R., & McGoron, A. J. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9383-z · Cited by 330
Mandal, A. K., Katuwal, S., Tettey, F., Gupta, A., Bhattarai, S., Jaisi, S., Bhandari, D. P., Shah, A. K., Bhattarai, N., & Parajuli, N. (2022) · Nanomaterials · doi:10.3390/nano12173066 · Cited by 321
Fate of polymeric nanocarriers for oral drug delivery
Plapied, L., Duhem, N., des Rieux, A., & Préat, V. (2011) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2010.12.005 · Cited by 320
Synthesis, Characterization, and Applications of Metal Nanoparticles
Shnoudeh, A. J., Hamad, I., Abdo, R. W., Qadumii, L., Jaber, A. Y., Surchi, H. S., & Alkelany, S. Z. (2019) · Biomaterials and Bionanotechnology · doi:10.1016/b978-0-12-814427-5.00015-9 · Cited by 309
Michen, B., Geers, C., Vanhecke, D., Endes, C., Rothen-Rutishauser, B., Balog, S., & Petri-Fink, A. (2015) · Scientific Reports · doi:10.1038/srep09793 · Cited by 289
Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications
Mohammadpour, R., Dobrovolskaia, M. A., Cheney, D. L., Greish, K. F., & Ghandehari, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.006 · Cited by 280
Self-citationPadrela, L., Rodrigues, M. A., Duarte, A., Dias, A. M. A., Braga, M. E. M., & de Sousa, H. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.010 · Cited by 262
Vitamin E-based nanomedicines for anti-cancer drug delivery
Duhem, N., Danhier, F., & Préat, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.009 · Cited by 253
Physicochemical characterization of drug nanocarriers
Berbel Manaia, E., Paiva Abuçafy, M., Chiari-Andréo, B. G., Lallo Silva, B., Oshiro-Júnior, J. A., & Chiavacci, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s133832 · Cited by 207
“2,9,25,26 There are several specific aspects of the DLS technique related to the equipment, data collection, and treatment.”
POxylation as an alternative stealth coating for biomedical applications
Bludau, H., Czapar, A. E., Pitek, A. S., Shukla, S., Jordan, R., & Steinmetz, N. F. (2017) · European Polymer Journal · doi:10.1016/j.eurpolymj.2016.10.041 · Cited by 112
Synthesis of metal nanoparticles using laser ablation technique
Mansoureh, G., & Parisa, V. (2018) · Emerging Applications of Nanoparticles and Architecture Nanostructures · doi:10.1016/b978-0-323-51254-1.00019-1 · Cited by 35
Metadata
- Authors
- Hall, J. B., Dobrovolskaia, M. A., Patri, A. K., & McNeil, S. E.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2007-12
- Volume
- 2
- Issue
- 6
- Pages
- 789-803
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2135913252
- Cited by
- 409
- References
- 61
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.